ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Other Events

Item 8.01.

On June 20, 2017, ARCA biopharma, Inc. (ARCA) provided a
GENETIC-AF clinical trial update.The press release is furnished
as Exhibit 99.1 hereto, the contents of which are incorporated
herein by reference.

Section 9 Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

ARCA biopharma, Inc. Exhibit
EX-99.1 2 abio-ex991_6.htm EX-99.1 abio-ex991_6.htm   Exhibit 99.1         ARCA Biopharma announces database lock for genetic-af Phase 2b interim efficacy analysis – DSMB Recommendation anticIpated in August 2017 ————————————————————————————————– GENETIC-AF Evaluating Gencaro as Potentially First Genetically-Targeted Treatment for Atrial Fibrillation ————————————————————————————————– Gencaro Development Program Previously Granted Fast Track Designation by U.S. FDA Westminster,…
To view the full exhibit click here
About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.